Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Total stock-based compensation expense recognized in by Year
Total stock-based compensation (SBC) expense recognized in income statement ($M) ($M)
Vertex Pharmaceuticals Total stock-based compensation expense recognized in: $686M in FY2025, down 1.8% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Note (Stock-based Compensation).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total stock-based compensation (SBC) expense recognized in income statement ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 686 | -1.8% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 699 | +20.2% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 581 | +18.3% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 491 | +11.3% | Form 10-K (filed 2025-02-13) ↗ |
| FY2021 | Dec 31, 2021 | 441 | +2.8% | Form 10-K (filed 2024-02-15) ↗ |
| FY2020 | Dec 31, 2020 | 430 | +19.1% | Form 10-K (filed 2023-02-10) ↗ |
| FY2019 | Dec 31, 2019 | 361 | +10.9% | Form 10-K (filed 2022-02-09) ↗ |
| FY2018 | Dec 31, 2018 | 325 | +10.9% | Form 10-K (filed 2021-02-11) ↗ |
| FY2017 | Dec 31, 2017 | 293 | +21.9% | Form 10-K (filed 2020-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 241 | +4.2% | Form 10-K (filed 2019-02-13) ↗ |
| FY2015 | Dec 31, 2015 | 231 | – | Form 10-K (filed 2018-02-15) ↗ |
Breakdown
What makes up total stock-based compensation expense recognized in
- SBC expense — Research and development ($M)415 · FY2025
- SBC expense — Selling, general and administrative ($M)259 · FY2025
- SBC expense — Cost of sales ($M)11.1 · FY2025
- SBC capitalized into inventory ($M)14.4 · FY2025
- Total gross stock-based compensation cost incurred (expensed + capitalized, $M)686 · FY2025
- Income tax benefit (provision) recognized for stock-based compensation ($M)129 · FY2025
- Stock-based compensation expense, net of tax ($M)557 · FY2025
Cite this data
StockData. (2026). Vertex Pharmaceuticals Total stock-based compensation expense recognized in ($M), annual FY2015–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/sbc-exp-tot
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.